RT Journal Article
SR Electronic
T1 Implementation of Individualised Polygenic Risk Score Analysis: A Test Case of a Family of Four
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.29.21259713
DO 10.1101/2021.06.29.21259713
A1 Corpas, Manuel
A1 Megy, Karyn
A1 Metastasio, Antonio
A1 Lehmann, Edmund
YR 2021
UL http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259713.abstract
AB Polygenic risk scores (PRS) have been widely applied in research studies, showing how population groups can be stratified into risk categories for many common conditions. As healthcare systems consider applying PRS to keep their populations healthy, little work has been carried out demonstrating their implementation at an individual level. We performed a systematic curation of PRS sources from established data repositories, selecting 27 phenotypes, comprising almost 40 million SNPs related to cancer, cardiovascular, metabolic and autoimmune diseases. We tested selected phenotypes using whole genome sequencing data for a family of four family related individuals, with the 1000 Genomes Project (1000G) Phase III participants as background populations. Over 98 billion allele effects were calculated in order to obtain the PRS for each of the individuals analysed here. PRS calculation for the 1000G cohort of 2,504 participants allows us to develop a methodology for risk inference and general PRS deployment. Our approach for PRS implementation advances the discussion on the adoption of PRS in a preventative healthcare setting.Competing Interest StatementAt the time of this writing, MC, KM, AM and EL are associated with Cambridge Precision Medicine Limited.Funding StatementThis research has been supported by Cambridge Precision Medicine Limited.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been independently assessed and approved by the Ethics Committee of Universidad Internacional de La Rioja (code PI:029/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sources of PRS used in this study are included in Table 3 and Table 4. The family genome variation data for this manuscript is not publicly available because they were not consented for open access. Request to access the family genome variation data should be directed to Manuel Corpas (m.corpas{at}cpm.onl).